Good news in the fight against the Corona pandemic have accompanied us during the last few weeks. On November 8th, the Mainz-based pharmaceutical company BioNTech and its American partner Pfizer announced that their vaccine is more than 90 percent effective in the decisive third round of tests. Exactly one week later, the US-based company Moderna presented similar promising data. The duo became a trio a week later: AstraZeneca also reported that its phase-3 tests were successful.
The American healthcare system is stigmatized in Europe, and especially in France, where the government is pretending to offer a high quality health services to every French citizen, regardless of his contribution to the social security. But if the French social security system succeed in one task – covering the uninsured, it failed in two others, much more important issues – controlling costs and innovation. A recent study edited by the Cato Institute is evidencing the superiority of the American healthcare system when it comes to innovation in medical treatment.